Albert David Limited has informed the Exchange regarding Board meeting held on August 02, 2025.
ALBERTDAVD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Albert David Limited announced its unaudited financial results for the quarter ended June 30, 2025. Revenue from operations fell sharply to Rs. 70.57 crore from Rs. 89.36 crore in the same quarter last year, a drop of about 21%. Profit after tax declined to Rs. 7.94 crore versus Rs. 18.84 crore in Q1 FY25, while EPS came in at Rs. 13.91 compared to Rs. 33.02 earlier. The statutory auditor L.B. Jha & Co. issued an unmodified (clean) limited review report. The Board also appointed Dr. Rajiv Anant Desai, a former Lupin executive with 38+ years of pharma experience, as an Additional Non-Executive Independent Director for five years, subject to shareholder approval via postal ballot.
The double-digit fall in both revenue and profit is a negative signal for near-term sentiment, though the company remains profitable. The new director brings strong pharma quality and regulatory expertise, which is a positive for governance and long-term credibility.